
BrainTrip is a neurotechnology company that leverages AI-driven analysis of brain waves to provide fast, affordable, non-invasive brain diagnostics primarily for cognitive health. Their flagship product, the BrainTrip CogniScore, is a CE-marked medical device that quantifies brain health and detects cognitive decline or dementia with high accuracy, specificity, and sensitivity. The company targets doctors' offices to enable point-of-care brain function testing with easy-to-interpret results and minimal training. BrainTrip's NeuroAI platform also supports drug discovery, personalized medicine, and large-scale EEG data analysis, positioning it as a leader in accessible brain health diagnostics and neuroscience acceleration.

BrainTrip is a neurotechnology company that leverages AI-driven analysis of brain waves to provide fast, affordable, non-invasive brain diagnostics primarily for cognitive health. Their flagship product, the BrainTrip CogniScore, is a CE-marked medical device that quantifies brain health and detects cognitive decline or dementia with high accuracy, specificity, and sensitivity. The company targets doctors' offices to enable point-of-care brain function testing with easy-to-interpret results and minimal training. BrainTrip's NeuroAI platform also supports drug discovery, personalized medicine, and large-scale EEG data analysis, positioning it as a leader in accessible brain health diagnostics and neuroscience acceleration.
Core product: CogniScore / BrainTrip Dementia Index — EEG-based brain-health scoring for cognitive decline detection
Regulatory status: CogniScore described as a CE-marked medical device
Tech focus: NeuroAI: AI-driven analysis of EEG/brainwave data
Headquarters: Ljubljana, Slovenia
Early detection and quantification of cognitive decline and brain aging using non-invasive EEG measurements.
2019
Biotechnology
Listed last funding date and an investor name in company snapshot; specific amount not disclosed in provided evidence.